This inventor holds 4 USPTO granted patents, plus 1 CIPO patent and 1 EPO patent. Top assignees: The Administrators of the Tulane Educational Fund, Mcgill University. Active years: 2013-2017.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
4 out of 249 
3 out of 570 
Years Active: 2013-2017
Title: Gloria S. Tannenbaum: Innovator in Ghrelin Receptor Research
Introduction
Gloria S. Tannenbaum is a prominent inventor based in Hampstead, CA. She has made significant contributions to the field of medical research, particularly in the area of obesity and metabolic disorders. With a total of 4 patents to her name, her work focuses on innovative methods for treating various health conditions.
Latest Patents
One of her latest patents is titled "Methods of inhibiting the ghrelin/growth hormone secretagogue receptor pathway and uses thereof." This invention provides methods for the treatment, prevention, or management of obesity, obesity-related disorders, diabetes mellitus, and metabolic syndrome. It involves administering a ghrelin O-acyltransferase (GOAT) inhibitor and/or a ghrelin receptor antagonist to the subject. The invention also details specific ghrelin receptor antagonists with a defined formula, which can be utilized in therapeutic applications.
Another significant patent is "Growth hormone secretagogue receptor antagonists and uses thereof." This invention introduces novel peptides that can modulate the ghrelin receptor, which is crucial for various medical conditions. These peptides serve as antagonists, inverse agonists, or partial agonists, providing potential treatments for metabolic and endocrine disorders, gastrointestinal issues, cardiovascular diseases, obesity, diabetes, and more.
Career Highlights
Throughout her career, Gloria has worked with esteemed institutions such as the Administrators of the Tulane Educational Fund and McGill University. Her research has been instrumental in advancing our understanding of ghrelin receptors and their implications in health.
Collaborations
Gloria has collaborated with notable colleagues, including Cyril Y. Bowers and David H. Coy. Their combined expertise has contributed to the success of her research endeavors.
Conclusion
Gloria S. Tannenbaum's innovative work in ghrelin receptor research has the potential to transform the treatment of obesity and related disorders. Her patents reflect her commitment to advancing medical science and improving patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile